Henderson Jane 4

What Happened
Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold a total of 2,000 shares in open-market transactions on May 1, 2026, generating approximately $164,080 in proceeds. The sales were reported as three lots: 811 shares at a weighted avg price of $81.02 ($65,707), 900 shares at $82.60 ($74,340), and 289 shares at $83.16 ($24,033). These were outright sales (S) and are typically routine rather than a direct buy signal.

Key Details

• Transaction date: May 1, 2026; Form 4 filed May 4, 2026 (within the 2-business-day filing window).
• Lots and reported weighted-average prices/values:
  • 811 shares @ $81.02 = $65,707 (prices ranged $80.640–$81.260) [F2]
  • 900 shares @ $82.60 = $74,340 (prices ranged $82.040–$82.995) [F3]
  • 289 shares @ $83.16 = $24,033 (prices ranged $83.090–$83.190) [F4]
• Total shares sold: 2,000; total proceeds: ~$164,080.
• Notable footnote: At least one transaction was executed pursuant to a Rule 10b5-1 trading plan adopted Sept 2, 2025 [F1].
• Shares owned after the transaction: not provided in the material supplied.

Context
Sales by executives can be for many reasons (diversification, taxes, scheduled plans). The presence of a 10b5-1 plan means at least part of these trades were prearranged and may be less informative about the CFO’s near-term view of the company. Purchases generally carry more weight as a bullish signal; this filing documents routine insider selling.